medigraphic.com

2012, Number 1

<< Back

Rev Cuba Endoc 2012; 23 (1)

Some considerations of endothelial dysfunction in patients presenting with hyperprolactinemia

Cabrera GM, Santana PF, Morales PLM

Language: Spanish
References: 36
Page:
PDF size: 61.98 Kb.


ABSTRACT

A review of the publications available of current situation on the subject related to endothelial dysfunction in patients with hyperprolactinemia: existence, production mechanisms and consequences. Taking into account that the hyperprolactinemia has a new approach related to endothelial dysfunction authors made present review. Above mentioned dysfunction is a alteration in the vascular relaxation provoked by decrease of relaxation factors derived from endothelium, mainly the nitric oxide, which cause an increase of vasoconstrictor stimulus with a pro-thrombotic trend of vasculature. The insulin resistance acts as a major factor of endothelial dysfunction associated or not with diabetes mellitus. Until now, the hyperprolactinemia status is associated with disorders of the glucose tolerance (decreased glucose tolerance with hyper-insulinemia). There is endothelial dysfunction in women with hyperprolactinemia and may be due to its relation to insulin resistance, to decrease of estrogens and to the own hyperprolactinemia. Also, there are inflammation's markers (the C-reactive protein) high in patients with this disease. The hyperprolactinemia is associated with the insulin resistance, the endothelial dysfunction and the low degree of inflammation, parameters determinant in the atherosclerosis process, thus, this disease may be a predisposing factor of the atherosclerosis becomes risk of cardiovascular morbidity and mortality.


REFERENCES

  1. Gokce N, Vita JA. Clinical manifestations of endotelial dysfunction. In: Loscalzo J, Schafer AI, editors. Thrombosis and Haemorrhage. Philadelphia, PA: Lippincott Williams and Wilkins; 2002. p. 685-706.

  2. Vehkavaaras S. Identification and treatment of endotelial dysfunction and cardiovascular risk markers in disorders of glucosa metabolism and in post menopausal women [monografía en internet]. Academic dissertation; 2001 [citado 14 de noviembre de 2011]. Disponible en: http://www.doria.fi/bitstream/handle/10024/2236/identifi.pdf?sequence=1

  3. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168-75.

  4. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113:1888-904.

  5. Pepine JG. Clinical implications of endothelial dysfunction. Clin Cardiol. 1998;21:795-9.

  6. Widlansky ME, Gorce N, Keany Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7):1149-60.

  7. Moncada S, Palmer RM, Higos EA. Nitric oxide physiology, pathophysiology, and farmacology. Pharmacol Rev. 1991;43:109-42.

  8. Steimberg HO, Chaker M, Leaming R, Johnsoin A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insuli resistance. J Clin Invest. 1996;97:2601-61.

  9. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and resistance. Diabetes Care. 2001;24(3):57-9.

  10. Arcaro G, Cretti A, Bazanos S, Lechi A, Muggeo M, Bonora E, et. al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-82.

  11. Leslie RD. United Kingdom Prospective Diabetes Study (UKPDS): What now or so wath? Diabetes Metab Res Rev. 2000;15:65:65-71.

  12. Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13:99-104.

  13. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinemia on glucose tolerance and insulin release in male and female rats. J Endocrinol. 1977;153:423-8.

  14. Santana F, Padrón R, Gonzáles R, Rodríguez L. Efecto de la hiperprolactinemia sobre el metabolismo hidrocarbonato. Rev Cubana Endocrinol. 2000;11(2):63-8.

  15. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, et. al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149(3):187-93.

  16. Nielsen JH. Effects of growth hormone, prolactin and placental lactógeno on insulin content and release and deoxyribonucleic acid synthesis in cultured pancreatic islets. Endocrinology. 1982;110:600-8.

  17. Nielsen JH, Nielsen V, Pedersen LM, Deckert T. Effects of pregnancy hormones on pancreatic islets in organ culture. Acta Endocrinológica. 1986;111:336-41.

  18. Seki K, Nagata I. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma. Gynecol Obstet Invest. 1991;31(4):222-5.

  19. Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hiperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 1985;28:138-42.

  20. Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome J. Clin Endocrinol Metabol. 2000; 85:1851-6.

  21. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999;340:115-26.

  22. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clinical Science. 2000;98:531-5.

  23. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham NJ, Dallinga-Thie GM, et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet. 2009 Aug;2(4):389-95.

  24. Aziz MM, Ishihara S, Rumi MA, Mishima Y, Oshima N, Kadota C, et al. Prolactin induces MFG-E8 production in macrophages via transcription factor C/EBP-dependent pathway. Apoptosis. 2008;13:609-20.

  25. Sun R, Li AL, Wei HM, Tian ZG. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res. 2004;14:67-73.

  26. Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Co-activation of platelets by prolactin or leptin-pathophysiological findings and clinical implications. Horm Metab Res. 2004;36:1-6.

  27. Wallaschofski M, Donné M, Eigenthaler B, Hentschel R, Faber H, Stepan M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metabolism. 2001;86:5912-9.

  28. Squizzato A, Gerdes VEA, Ageno W, Buller HR. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med. 2007;2:76-83.

  29. Wallaschofski H, Kobsar A, Koksch M, Siegemund A, Hentschel B, Tuschy U, et al. Prolactin receptor signalling during platelet activation. Horm Metab Res. 2003;35:228-35.

  30. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thrombosis and Haemostasis. 2006;96:38-44.

  31. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, et al. Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Hormone and Metabolic Research. 2006;38:767-72.

  32. Franchini M, Targher G, Montagnana M & Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thrombosis Research. 2008;122:727-35.

  33. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemostasis. 2008;99:995-1000.

  34. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, et al. Prolactin and Preclinical Atherosclerosis in Menopausal Women With Cardiovascular Risk Factors. Am J Hypertens. 2011;24(5):569-73.

  35. Stumpe KO, Kolloch R, Higuchi M, Kruk F, Vetter H. Hyperprolactinemia and antihypertensive effect of bromocriptine in essential hypertension: identification of abnormal central dopamine control. Lancet. 1977;2:211-4.

  36. Stamatelopoulos KS, Georgiopoulos GA, Sfikakis PP, Kollias G, Manios E, Mantzou E, et al. Pilot study of circulating prolactin levels and endothelial function in men with hypertension. Curr Pharm Des. 2004;10(29):3591-605.




2020     |     www.medigraphic.com